Cardiac sympathetic imaging with mIBG in heart failure.
Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF.
Hospital Sant Pau, Barcelona, Spain. icarrio@santpau.cat
Ignasi
I
Carrió
Martin R
MR
Cowie
Junichi
J
Yamazaki
James
J
Udelson
Paolo G
PG
Camici
D019797:3-Iodobenzylguanidine; D001145:Arrhythmias, Cardiac / Q000000981:diagnostic imaging / Q000209:etiology / Q000503:physiopathology; D016757:Death, Sudden, Cardiac / Q000209:etiology; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging* / Q000294:innervation*; D006333:Heart Failure / Q000150:complications / Q000000981:diagnostic imaging* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D018570:Risk Assessment; D013564:Sympathetic Nervous System / Q000000981:diagnostic imaging* / Q000503:physiopathology; D014055:Tomography, Emission-Computed / Q000379:methods*; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine